Help me increase lung cancer survival!
EGFR positive lung cancer is the most common form of non-small cell lung cancer, representing over 32% of cases worldwide, and is more common in woman in than men. Diagnosis of lung cancer among women —often young women with little kids —who have never smoked is on an alarming rise.
More people die of lung cancer annually than colorectal, breast and prostate cancers combined. Yet at this time, only 6% of federal funding goes towards lung cancer research and much less private philanthropy.
New genetically targeted therapies for EGFR have made huge inroads into changing what it means to have a lung cancer diagnosis with people living longer and better lives. However, eventually the cancer mutates again and outsmarts these therapies as it did with me. Please join me to fund research to find new treatments to combat this resistance.
That is where the EGFR Resisters and the Lung Cancer Research Foundation come in. EGFR Resisters are a grassroots patient-driven community dedicated to changing the outcome of EGFR positive lung cancer, and LCRF is focused on funding innovative research that has the potential to extend survival and improve the quality of life. They’ve joined forces to fund the best possible research for EGFR positive lung cancer.
This means three projects will be chosen by leaders of the EGFR Resisters and LCRF’s Scientific Advisory Board, in a rigorous two-step process, to fund the most promising research in the field. The first of three grantees will be announced on November 17th with next two following in 2022.
GOAL EXCEEDED! MATCH MADE! Our overall goal is to fund three researchers in total and my goal is to raise $15,000 by December 31st to make these efforts possible. Thank you for helping me exceed my goal!
100% of your funds for this campaign will go directly to research.
If you think this page contains objectionable content, please inform the system administrator.